Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Partners to Develop Methodologies for Ensuring Quality of Stem Cell Production

By BiotechDaily International staff writers
Posted on 12 Nov 2012
Biotech companies from the United States and Europe have recently announced an agreement to cooperate on the development of methodologies to enable the consistent production of large quantities of stem cells for research and clinical use.

The American company EMD Millipore (Billerica, MA, USA) offers a broad range of innovative products, services, and business relationships in research, development, and production of biotech and pharmaceutical drug therapies. EMD Millipore is the life science division of Merck KGaA, (Darmstadt, Germany).

The other partner to the agreement is Sistemic Ltd. (Glasgow, United Kingdom). Sistemic is a leading provider of microRNA-based problem-solving services and kit-based products. Their extensive suite of tools for the cell therapy community includes SistemQCT, which is used to characterize cells including stem cells with regard to cell identity, purity, potency, and safety as well as monitoring production quality control. In addition, the drug development market is served through a range of products which include SistemTOXT, SistemKBT, and SistemRNAT.

Under terms of the newly announced agreement the companies will jointly develop proprietary monitoring methodology utilizing Sistemic's microRNA marker detection capability to enable consistent growth of stem cells in EMD Millipore's Mobius CellReady platform. Markers developed in the course of this project may also be incorporated into commercially available kits for quality control of stem cells cultures.

"To advance the progress of stem cell products toward clinical use, it is critical to ensure the consistency and quality of large-scale culture systems," said Robert Shaw, commercial director of EMD Millipore's Stem Cell Initiative. "We are excited to be partnering with Sistemic, as the company's leading microRNA-based solutions will help us continue our efforts toward the commercialization of stem cell processing."

"We are delighted to enter this collaborative arrangement with EMD Millipore," said Jim Reid, CEO of Sistemic. "The fact that EMD Millipore has chosen Sistemic as its collaborative partner is yet another validation of our ground-breaking research and ability to develop systems for quality control of stem cells, and other mutually beneficial products and programs."

Related Links:
EMD Millipore
Merck KGaA
Sistemic Ltd.


RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.